Risk factor assessment and counselling for 12 months reduces metabolic and cardiovascular risk in overweight or obese patients with schizophrenia spectrum disorders: The CRESSOB study;La evaluacion de factores de riesgo y el asesoramiento durante 12 meses reduce el riesgo metabolico y cardiovascular en pacientes con trastornos del espectro esquizofrenico con sobrepeso u obesidad: Estudio CRESSOB

Actas Espanolas de Psiquiatria

Volumn 44, Issue 1, 2016, Pages 20-29

  Gutierrez Rojas, Luis ^a   Pulido, Susana ^b   Azanza, Jose R ^c   Bernardo, Miguel ^d,e,f,g   Rojo, Luis ^h   Mesa, Francisco J ^b   Martinez Ortega, Jose M ⁱ  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b PFIZER INC   (United States)

^c UNIVERSITY OF NAVARRA   (Spain)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

^g UNIVERSITY OF BARCELONA   (Spain)

^h HOSPITAL UNIVERSITARIO LA FE   (Spain)

ⁱ UNIVERSITY OF GRANADA   (Spain)

Author keywords

Cardiovascular Disease; Metabolic Syndrome; Overweight; Schizophrenia

Indexed keywords

ADULT; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COUNSELING; FEMALE; HEALTH PROMOTION; HUMAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTICENTER STUDY; OBESITY; OVERWEIGHT; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RISK FACTOR; SCHIZOPHRENIA; SPAIN;

ADULT; CARDIOVASCULAR DISEASES; COUNSELING; FEMALE; HEALTH PROMOTION; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; OVERWEIGHT; PROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA; SPAIN;

EID: 84959899075     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150:1115-21.
2. Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry. 2004;49:753-60.
3. Gupta S, Steinmeyer C, Frank B, Maudhusoodanan S, Lockwood K, Lentz B, et al. Hyperglycemia and hypertriglicerdiemia in real world patients on antipsychotic therapy. Am J Ther. 2003;10:348-55.
4. Suvisaari JM, Saarni SI, Perala J, Suvisaari JVJ, Harkanen T, Lonnqvist J, et al. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J Clin Psychiatry. 2007;68:1045-55.
5. Suvisaari J, Perala J, Saarni SL, Harkanen T, Pirkola S, Joukamaa M, et al. Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey. Eur Arch Psychiatry Clin Neurosci. 2008;258:129-36.
6. Bobes J, Arango C, Garcia-Garcia M, Rejas J. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophr Res. 2010;119:101-9.
7. de Leon J, Susce MT, Diaz FJ, Rendon DM, Velasquez DM. Variables associated with alcohol, drug, and daily smoking cessation in patients with severe mental illnesses. J Clin Psychiatry. 2005;66:1447-55.
8. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med. 1999;29:697-701.
9. Samele C, Patel M, Boydell J, Leese M, Wessely S, Murray R. Physical illness and lifestyle risk factors in people with their first presentation of psychosis. Soc Psychiatry Psychiatr Epidemiol. 2007;42:117-24.
10. Daumit GL, Goldberg RW, Anthony C, Dickerson F, Brown CH, Kreyenbuhl J, et al. Physical activity patterns in adults with severe mental illness. J Nerv Ment Dis. 2005;193:641-6.
11. McCreadie RG. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry. 2003;183:534-9.
12. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-96.
13. Arango C, Bobes J, Aranda P, Carmena R, Garcia-Garcia M, Rejas J, Grp, C.S.C. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: Findings from the CLAMORS study. Schizophr Res. 2008;104:1-12.
14. Henderson DC. Weight gain with atypical antipsychotics: Evidence and insights. J Clin Psychiatry. 2007;68:18-26.
15. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-23.
16. Sicras-Mainar A, Blanca-Tamayo M, Rejas-Gutierrez J, Navarro- Artieda R. Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: A crosssectional assessment of a primary health care database. Eur Psychiatry. 2008;23:100-8.
17. Simon GE, Von Korff M, Saunders K, Miglioretti DL, Crane PK, van Belle G, et al. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry. 2006;63:824-30.
18. Bresee LC, Majumdar SR, Patten SB, Johnson JA. Prevalence of cardiovascular risk factors and disease in people with schizophrenia: A population-based study. Schizophr Res. 2010; 117:75-82.
19. Association AD, Association AP, Endocrinologists AAoC, Obesity, NAAftSo. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
20. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RIG, Moller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009;24:412-24.
21. Rodriguez-Artalejo F, Baca E, Esmatjes E, Merino-Torres JF, Monereo S, Moreno B, et al. Assessment and control of metabolic and cardiovascular risk in patients with schizophrenia. Med Clin. 2006;127:542-8.
22. Ruiz JS, Garcia JB, Ruiloba JV, Ubago JG, Gonzalez MPGP; Schizop WGPHP. Consensus on physical health of patients with schizophrenia from the Spanish Societies of Psychiatry and Biological Psychiatry. Actas Esp Psiquiatr. 2008;36:251-64.
23. Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev. 2007;24:CD005148.
24. Loh C, Meyer JM, Leckband SG. A comprehensive review of behavioral interventions for weight management in schizophrenia. Ann Clin Psychiatry. 2006;18:23-31.
25. First MB, Spitzer RL, Gibbon M, Willaims JBW. Structured Clinical Interview for DSM-IV Axis I Disorders-Clinician Version (SCIDI- CV). New York State Psychiatric Institute, Biometrics Research Department, New York, NY; 1996.
26. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association; 1994.
27. Gutierrez-Rojas L, Azanza JR, Bernardo M, Rojo L, Mesa F, Martinez-Ortega JM. Prevalence of Metabolic Syndrome in Spanish Patients with Schizophrenia and Overweight. The CRESSOB Study. Actas Esp Psiquiatr. 2014;42:9-18.
28. World Medical Association (WMA) Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects (2004) http://www.wma.net/e/policy/b3.htm. Updated 2004. Accessed july 2014.
29. World Health Organization. Body Mass Index (BMI). Available at: http://www.euro.who.int/en/what-we-do/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-massindex- bmi
30. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factors categories. Circulation. 1998;97:1837-47.
31. Expert Panel on Detection and Evaluation of Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
32. Peralta V, Cuesta M. Psychometric properties of the Positive and Negative Syndrome Scale (PANSS) in schizophrenia. Psychiatr Res. 1994;53:31-40.
33. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-76.
34. Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus. Am J Psychiatry. 2005;162:441-9.
35. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The Global Assessment Scale: A procedure for measuring overall severity of psychiatric disturbances. Arch Gen Psychiatry. 1976;33:766-71.
36. EuroQoL Group. EuroQoL - a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199-298.
37. Prieto L, Sacristan JA, Ormaechea JA, Casado A, Badia X, Gomez JC. Psychometric validation of a generis health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients. Curr Med Res Opin. 2004;20:827-35.
38. Schwartz RC. Concurrent validity of the Global Assessment of Functioning Scale for clients with schizophrenia. Psychol Rep. 2007;100:571-4.
39. De Hert M, Cohen D, Bobes J, Cetkovich-Bakmas M, Leucht S, Ndetei DM, et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry. 2011;10:138-51.
40. Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C, Gleeson JF, McGorry PD. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry. 2008;193:101-7.
41. Holt RI, Peveler RC, Byrne CD. Schizophrenia, the metabolic syndrome and diabetes. Diabet Med. 2004;21:515-23.
42. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-23.
43. Wahlbeck K, Tuunainen A, Ahokas A, Leucht S. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology (Berl). 2001;155:230-3.
44. Saari KM, Lindeman SM, Viilo KM, Isohanni MK, Jarvelin MR, Lauren LH, et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: The Northern Finland 1966 Birth Cohort study. J Clin Psychiatry. 2005;66:559-63.
45. Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J; CLAMORS Study Collaborative Group. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS study. Schizophr Res. 2007;90:162-73.
46. Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80:45-53.
47. Gurpegui M, Martinez-Ortega JM, Gutierrez-Rojas L, Rivero J, Rojas C, Jurado D. Overweight and obesity in patients with bipolar disorder or schizophrenia compared with a nonpsychiatric sample. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37:169-75.
48. Saarni SE, Saarni SI, Fogelholm M, Heliovaara M, Perala J, Suvisaari J, et al. Body composition in psychotic disorders: a general population survey. Psychol Med. 2009;39:801-10.
49. Taylor D, Young C, Mohamed R, Paton C, Walwyn R. Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs. J Psychopharmacol. 2005;19:182-6.
50. Barnett AH, Mackin P, Chaudhury I, Farooqi A, Gadsby R, Heald A, et al. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol. 2007;21:357-73.
51. Citrome L. Metabolic syndrome and cardiovascular disease. J Psychopharmacol. 2005;19:84-93.
52. Li C, Zhan G, Rao S, Zhang H. Metabolic syndrome and its factors affect cognitive function in chronic schizophrenia complicated by metabolic syndrome. J Nerv Ment Dis. 2014;202(4):313-8.
53. Hermes E, Nasrallah H, Davis V, Meyer J, McEvoy J, Goff D, et al. The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophr Res. 2011;128:166-70.
54. Volavka J, Czobor P, Derks EM, Bitter I, Libiger J, Kahn RS, et al. Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). J Clin Psychiatry. 2011;72:955-61.
55. Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006;86:15-22.
56. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001;62:22-31.
57. Gortmaker SL, Must A, Perrin JM, Sobol AM, Dietz WH. Social and economic consequences of overweight in adolescence and young adulthood. N Engl J Med. 1993;329:1008-12.
58. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand. 2002;106:286-90.
59. Weiden PJ, Mackell JA, McDonnell DD. Obesity ad a risk factor for antipsychotic noncompliance. Schizophr Res. 2004;66:51-7.